

IG	Titolo del progetto	Punteggio ottenuto	Punteggio massimo
Fornarini	<i>Immune Tumor MicroEnvironment in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma treated with nivolumab: ancillary study of the Meet-URO 15 I-BIO-REC study (Meet-URO 15 I-TME)</i>	164	200
Ghiorzo	<i>Beyond BRCA: hereditary cancer predisposition and personalized therapy by multigene panel testing in pancreatic cancer patients</i>	163	200
Ottini	<i>Germline and somatic characterization of male breast cancer for new molecular biomarker discovery</i>	162	200
Capalbo	<i>Galectins as target and predictive biomarkers in Immune checkpoint inhibitors therapy: a multicentric study</i>	161	200
Dellambra	<i>BDNF/TrkB axis as a source for squamous cell carcinoma prognostic biomarkers and therapeutic target</i>	158	200
Ferrero	<i>Minimally and non-invasive methods for early detection and/or progression of endometrial cancer</i>	158	200
Cardone	<i>Repurposing FDA-approved drugs for effective targeted therapy in KRAS-dependent Pancreatic Ductal Adenocarcinoma</i>	157	200
Bossi	<i>Identification of novel therapeutic opportunities for metastatic colorectal cancer patients</i>	155	200
D'Orazi	<i>Endoplasmic reticulum (ER) stress signaling and chemotherapy resistance in solid cancers: investigating the interplay between unfolded protein response (UPR) and p53 to uncover potential novel biological biomarkers</i>	153	200
Venuti	<i>New prognostic and predictive biomarkers for HPV-associated oropharyngeal cancer</i>	152	200
Alisi	<i>Identification of new translational biomarkers of pro-fibrogenic and pro-carcinogenic phenotype in Non-alcoholic fatty liver disease (NAFLD)</i>	150	200
Fattore	<i>Therapeutic and diagnostic implications of miR-4488 and miR-4443 to fight resistance to targeted therapy in metastatic melanoma</i>	143	200
Neri	<i>Characterization of the role of Notch and identification of novel molecular and genetic determinants promoting growth, survival and chemoresistance in B-Acute Lymphoblastic Leukemia</i>	139	200
De Petro	<i>COMPARE: study of extraCellular vesicle non-Coding RNAs s for Monitoring the Response to soraAfenib treatment in hEpatocellular carcinoma: versus a liquid dynamic medicine</i>	138	200
Trivedi	<i>MicroRNA And Immune Checkpoint Blockade in B cell Lymphoma: Evaluation and Restoration of Tumor Immunogenicity in three dimensional biomimetic models</i>	127	200
Bon	<i>Dissecting Darpp-32 predictive potential for T-DM1 response of HER2-positive advanced breast cancer patients: a prospective study</i>	122	200
Chessa	<i>Melanoma in childhood and adolescence: first step to prevention</i>	113	200
Facchiano	<i>Modulating ion channels to improve antimelanoma activity</i>	113	200
Meleti	<i>Research of metabolic and inflammatory salivary biomarkers for oral carcinoma</i>	96	200
Bravaccini	<i>Spotlight on tumor microenvironment, PSMA and AR as targetable biomarkers in triple negative breast cancer (TNBC)</i>	93	200
Rulli	<i>Intraoperative enumeration and bio-pathological evaluation of Circulating Tumor Cells (CTC) from tumor venous blood (lateral thoracic vein) during breast cancer surgery</i>	90	200
Carozzi	<i>Liquid biopsy and sputum biomarkers to assess the risk for lung cancer in subjects targeted for Low Dose Computed Tomography (LDCT) screening. Validation of innovative biomarkers</i>	87	200
Di Lorenzo	<i>A phase II study of durvalumab (MEDI4736) in patients with poor performance status as first-line treatment for advanced urothelial cancer: the DURWIN trial</i>	85	200
Mearini	<i>Diagnosis of prostate cancer (Pca) through molecular assessment in biological fluids and prostate biopsies</i>	67	200
Pezzella	<i>Serratus plane block in pain management of breast conserving surgery: feasibility and effectiveness of intraoperative "open" application vs US-guided one, pilot study</i>	63	200